Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Rohit Aggarwal, MD, MS

University of Pittsburgh
Pittsburgh, PA, United States

Dr. Aggarwal is a professor of medicine at University of Pittsburgh and medical director of Arthritis and Autoimmunity Center at University of Pittsburgh Medical Center. He is the co-Director of UPMC Myositis Center. His research and clinical areas of interest are clinical and translational research in inflammatory muscle diseases (myositis) and associated interstitial lung disease. He is the past-chair of the medical advisory board of The Myositis Association (TMA) as well as past-chair of the scientific committee of IMACS, which are the largest patient and physician groups working in the field of myositis, respectively.

Presentation(s):

  • The Classification Criteria of Anti-Synthetase Syndrome

    Monday, November 13, 2023
    2:30 PM – 2:45 PM PT

    Disclosure(s): Actigraph: Consultant (Ongoing); Alexion: Consultant (Ongoing); ANI Pharmaceuticals: Consultant (Ongoing); Argenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); CabalettaBio: Consultant (Ongoing); Capella Bioscience: Consultant (Ongoing); Corbus: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); EMD Serono: Consultant (Ongoing), Grant/Research Support (Ongoing); Galapagos: Consultant (Ongoing); Horizon Therapeutics: Consultant (Ongoing); I-Cell: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Kezar: Consultant (Ongoing); Kyverna: Consultant (Ongoing); Mallinckrodt: Grant/Research Support (Ongoing); Merck: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Q32: Grant/Research Support (Ongoing); Roivant: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Teva: Consultant (Ongoing)

  • 1946: Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis

    Tuesday, November 14, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): Actigraph: Consultant (Ongoing); Alexion: Consultant (Ongoing); ANI Pharmaceuticals: Consultant (Ongoing); Argenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); CabalettaBio: Consultant (Ongoing); Capella Bioscience: Consultant (Ongoing); Corbus: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); EMD Serono: Consultant (Ongoing), Grant/Research Support (Ongoing); Galapagos: Consultant (Ongoing); Horizon Therapeutics: Consultant (Ongoing); I-Cell: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Kezar: Consultant (Ongoing); Kyverna: Consultant (Ongoing); Mallinckrodt: Grant/Research Support (Ongoing); Merck: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Q32: Grant/Research Support (Ongoing); Roivant: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Teva: Consultant (Ongoing)

  • 2576: Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study

    Wednesday, November 15, 2023
    9:30 AM – 9:40 AM PT

    Disclosure(s): Actigraph: Consultant (Ongoing); Alexion: Consultant (Ongoing); ANI Pharmaceuticals: Consultant (Ongoing); Argenx: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Grant/Research Support (Ongoing); CabalettaBio: Consultant (Ongoing); Capella Bioscience: Consultant (Ongoing); Corbus: Consultant (Ongoing); CSL Behring: Consultant (Ongoing); EMD Serono: Consultant (Ongoing), Grant/Research Support (Ongoing); Galapagos: Consultant (Ongoing); Horizon Therapeutics: Consultant (Ongoing); I-Cell: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Kezar: Consultant (Ongoing); Kyverna: Consultant (Ongoing); Mallinckrodt: Grant/Research Support (Ongoing); Merck: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Q32: Grant/Research Support (Ongoing); Roivant: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Teva: Consultant (Ongoing)